 Connection
Co-Authors
This is a "connection" page, showing publications co-authored by Yvonne Yau and Felix Ratjen.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.634 |
|
|
|
-
Ratjen F, Waters V, Klingel M, McDonald N, Dell S, Leahy TR, Yau Y, Grasemann H. Changes in airway inflammation during pulmonary exacerbations in patients with cystic fibrosis and primary ciliary dyskinesia. Eur Respir J. 2016 Mar; 47(3):829-36.
Score: 0.178
-
Waters VJ, Stanojevic S, Sonneveld N, Klingel M, Grasemann H, Yau YC, Tullis E, Wilcox P, Freitag A, Chilvers M, Ratjen FA. Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patients. J Cyst Fibros. 2015 Nov; 14(6):755-62.
Score: 0.168
-
Yau YC, Ratjen F, Tullis E, Wilcox P, Freitag A, Chilvers M, Grasemann H, Zlosnik J, Speert D, Corey M, Stanojevic S, Matukas L, Leahy TR, Shih S, Waters V. Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients. J Cyst Fibros. 2015 Mar; 14(2):262-6.
Score: 0.165
-
Waters V, Atenafu EG, Lu A, Yau Y, Tullis E, Ratjen F. Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients. J Cyst Fibros. 2013 Sep; 12(5):482-6.
Score: 0.146
-
Waters V, Stanojevic S, Atenafu EG, Lu A, Yau Y, Tullis E, Ratjen F. Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur Respir J. 2012 Jul; 40(1):61-6.
Score: 0.135
-
Waters V, Atenafu EG, Salazar JG, Lu A, Yau Y, Matukas L, Tullis E, Ratjen F. Chronic Stenotrophomonas maltophilia infection and exacerbation outcomes in cystic fibrosis. J Cyst Fibros. 2012 Jan; 11(1):8-13.
Score: 0.132
-
Waters V, Yau Y, Prasad S, Lu A, Atenafu E, Crandall I, Tom S, Tullis E, Ratjen F. Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease. Am J Respir Crit Care Med. 2011 Mar 01; 183(5):635-40.
Score: 0.124
-
Al-Saleh S, Dell SD, Grasemann H, Yau YC, Waters V, Martin S, Ratjen F. Sputum induction in routine clinical care of children with cystic fibrosis. J Pediatr. 2010 Dec; 157(6):1006-1011.e1.
Score: 0.123
-
Lam W, Tjon J, Seto W, Dekker A, Wong C, Atenafu E, Bitnun A, Waters V, Yau Y, Solomon M, Ratjen F. Pharmacokinetic modelling of a once-daily dosing regimen for intravenous tobramycin in paediatric cystic fibrosis patients. J Antimicrob Chemother. 2007 Jun; 59(6):1135-40.
Score: 0.098
-
Somayaji R, Yau YCW, Tullis E, LiPuma JJ, Ratjen F, Waters V. Clinical Outcomes Associated with Burkholderia cepacia Complex Infection in Patients with Cystic Fibrosis. Ann Am Thorac Soc. 2020 Jul 17.
Score: 0.061
-
Middleton MA, Layeghifard M, Klingel M, Stanojevic S, Yau YCW, Zlosnik JEA, Coriati A, Ratjen FA, Tullis ED, Stephenson A, Wilcox P, Freitag A, Chilvers M, McKinney M, Lavoie A, Wang PW, Guttman DS, Waters VJ. Epidemiology of Clonal Pseudomonas aeruginosa Infection in a Canadian Cystic Fibrosis Population. Ann Am Thorac Soc. 2018 07; 15(7):827-836.
Score: 0.053
-
Blanchard AC, Rooney AM, Yau Y, Zhang Y, Stapleton PJ, Horton E, Klingel M, Stanojevic S, Ratjen F, Coburn B, Waters V. Early detection using qPCR of Pseudomonas aeruginosa infection in children with cystic fibrosis undergoing eradication treatment. J Cyst Fibros. 2018 11; 17(6):723-728.
Score: 0.052
-
Waters V, Yau Y, Beaudoin T, Wettlaufer J, Tom SK, McDonald N, Rizvi L, Klingel M, Ratjen F, Tullis E. Pilot trial of tobramycin inhalation powder in cystic fibrosis patients with chronic Burkholderia cepacia complex infection. J Cyst Fibros. 2017 Jul; 16(4):492-495.
Score: 0.049
-
Wettlaufer J, Klingel M, Yau Y, Stanojevic S, Tullis E, Ratjen F, Waters V. Longitudinal study of Stenotrophomonas maltophilia antibody levels and outcomes in cystic fibrosis patients. J Cyst Fibros. 2017 01; 16(1):58-63.
Score: 0.046
-
Stanojevic S, Ratjen F, Stephens D, Lu A, Yau Y, Tullis E, Waters V. Factors influencing the acquisition of Stenotrophomonas maltophilia infection in cystic fibrosis patients. J Cyst Fibros. 2013 Dec; 12(6):575-83.
Score: 0.037
-
Warren TA, Yau Y, Ratjen F, Tullis E, Waters V. Serum galactomannan in cystic fibrosis patients colonized with Aspergillus species. Med Mycol. 2012 Aug; 50(6):658-60.
Score: 0.035
-
Leahy TR, Yau YC, Atenafu E, Corey M, Ratjen F, Waters V. Epidemiology of borderline oxacillin-resistant Staphylococcus aureus in pediatric cystic fibrosis. Pediatr Pulmonol. 2011 May; 46(5):489-96.
Score: 0.032
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|